Literature DB >> 33346004

Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.

Yuta Myojin1, Hayato Hikita1, Masaya Sugiyama2, Yoichi Sasaki1, Kenji Fukumoto1, Sadatsugu Sakane1, Yuki Makino1, Nobuyuki Takemura3, Ryoko Yamada1, Minoru Shigekawa1, Takahiro Kodama1, Ryotaro Sakamori1, Shogo Kobayashi4, Tomohide Tatsumi1, Hiroshi Suemizu5, Hidetoshi Eguchi4, Norihiro Kokudo3, Masashi Mizokami2, Tetsuo Takehara6.   

Abstract

BACKGROUND & AIMS: Although the tumor microenvironment plays an important role in tumor growth, it is not fully understood what role hepatic stellate cells (HSCs) play in the hepatocellular carcinoma (HCC) microenvironment.
METHODS: A high-fat diet after streptozotocin was administered to HSC-specific Atg7-deficient (GFAP-Atg7 knockout [KO]) or growth differentiation factor 15 (GDF15)-deficient (GFAP-GDF15KO) mice. LX-2 cells, a human HSC cell line, were cultured with human hepatoma cells.
RESULTS: In the steatohepatitis-based tumorigenesis model, GFAP-Atg7KO mice formed fewer and smaller liver tumors than their wild-type littermates. Mixed culture of LX-2 cells and hepatoma cells promoted LX-2 cell autophagy and hepatoma cell proliferation, which were attenuated by Atg7 KO in LX-2 cells. Hepatoma cell xenograft tumors grew rapidly in the presence of LX-2 cells, but Atg7 KO in LX-2 cells abolished this growth. RNA-sequencing revealed that LX-2 cells cultured with HepG2 cells highly expressed GDF15, which was abolished by Atg7 KO in LX-2 cells. GDF15 KO LX-2 cells did not show a growth-promoting effect on hepatoma cells either in vitro or in the xenograft model. GDF15 deficiency in HSCs reduced liver tumor size caused by the steatohepatitis-based tumorigenesis model. GDF15 was highly expressed and GDF15-positive nonparenchymal cells were more abundant in human HCC compared with noncancerous parts. Single-cell RNA sequencing showed that GDF15-positive rates in HSCs were higher in HCC than in background liver. Serum GDF15 levels were high in HCC patients and increased with tumor progression.
CONCLUSIONS: In the HCC microenvironment, an increase of HSCs that produces GDF15 in an autophagy-dependent manner may be involved in tumor progression.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell–Cell Interaction; Liver Cancer

Year:  2020        PMID: 33346004     DOI: 10.1053/j.gastro.2020.12.015

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

Review 1.  Macrophage inhibitory cytokine-1 in cancer: Beyond the cellular phenotype.

Authors:  Sakthivel Muniyan; Ramesh Pothuraju; Parthasarathy Seshacharyulu; Surinder K Batra
Journal:  Cancer Lett       Date:  2022-03-26       Impact factor: 9.756

2.  GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma.

Authors:  Yanying Li; Jingliang Wu; Qiao Lu; Xuemin Liu; Jiaxuan Wen; Xiaohui Qi; Jianhao Liu; Bo Lian; Bo Zhang; Hengyi Sun; Guixiang Tian
Journal:  Int J Nanomedicine       Date:  2022-06-07

3.  Sulfatase 2-Induced Cancer-Associated Fibroblasts Promote Hepatocellular Carcinoma Progression via Inhibition of Apoptosis and Induction of Epithelial-to-Mesenchymal Transition.

Authors:  Cong Wang; Chuzhi Shang; Xiaohong Gai; Tao Song; Shaoshan Han; Qingguang Liu; Xin Zheng
Journal:  Front Cell Dev Biol       Date:  2021-04-06

4.  Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma.

Authors:  Boyuan Liu; Zewei Zhou; Yu Jin; Jinying Lu; Dongju Feng; Rui Peng; Hua Sun; Xiaoxin Mu; Changxian Li; Yun Chen
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

Review 5.  Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities.

Authors:  Ester García-Pras; Anabel Fernández-Iglesias; Jordi Gracia-Sancho; Sofía Pérez-Del-Pulgar
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

Review 6.  Review: Challenges of In Vitro CAF Modelling in Liver Cancers.

Authors:  Alba Herrero; Elisabeth Knetemann; Inge Mannaerts
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

7.  Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.

Authors:  Yuta Myojin; Takahiro Kodama; Ryotaro Sakamori; Kazuki Maesaka; Takayuki Matsumae; Yoshiyuki Sawai; Yasuharu Imai; Kazuyoshi Ohkawa; Masanori Miyazaki; Satoshi Tanaka; Eiji Mita; Seiichi Tawara; Takayuki Yakushijin; Yasutoshi Nozaki; Hideki Hagiwara; Yuki Tahata; Ryoko Yamada; Hayato Hikita; Tomohide Tatsumi; Tetsuo Takehara
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

8.  Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.

Authors:  Ying Wang; Chaojie Chen; Jiajun Chen; Tingting Sang; He Peng; Xiaojian Lin; Qian Zhao; Shengjia Chen; Thomas Eling; Xingya Wang
Journal:  Redox Biol       Date:  2022-04-27       Impact factor: 10.787

Review 9.  Resident Immune Cells of the Liver in the Tumor Microenvironment.

Authors:  Yunjie Lu; Shiying Ma; Wei Ding; Pengcheng Sun; Qi Zhou; Yunfei Duan; Kurt Sartorius
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

10.  The Clinical Value of GDF15 and Its Prospective Mechanism in Sepsis.

Authors:  Huan Li; Dongling Tang; Juanjuan Chen; Yuanhui Hu; Xin Cai; Pingan Zhang
Journal:  Front Immunol       Date:  2021-09-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.